Elevated plasma glucosylsphingosine in Gaucher disease: Relation to phenotype, storage cell markers, and therapeutic response

Blood

Volumn 118, Issue 16, 2011, Pages

  Dekker, Nick ^a   Van Dussen, Laura ^a   Hollak, Carla E M ^a   Overkleeft, Herman ^b   Scheij, Saskia ^a   Ghauharali, Karen ^a   Van Breemen, Mariëlle J ^a   Ferraz, Maria J ^a   Groener, Johanna E M ^a   Maas, Mario ^a   Wijburg, Frits A ^a   Speijer, Dave ^a   Tylki Szymanska, Anna ^c   Mistry, Pramod K ^d   Boot, Rolf G ^a   Aerts, Johannes M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCL18; CELL MARKER; CHITOTRIOSIDASE; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; GLUCOSYLSPHINGOSINE; GLYCOSPHINGOLIPID; LYSOGLYCOSPHINGOLIPID; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MANNOSE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INACTIVATION; FEMALE; GAUCHER DISEASE; GENOTYPE; HUMAN; MACROPHAGE; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

EID: 80054841258     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-05-352971     Document Type: Article

References (50)

1. Beutler E, Grabowski G. Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Diseases. New York, NY: McGraw-Hill. 2001; 3635-3668.
2. Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med. 1991; 324(21):1464-1470.
3. Aerts JM, Yasothan U, Kirkpatrick P. Velaglucerase alfa. Nat Rev Drug Discov. 2010;9(11): 837-838.
4. Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet. 2000;355(9214): 1481-1485. (Pubitemid 30237353)
5. Platt FM, Jeyakumar M, Andersson U, et al. Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. J Inherit Metab Dis. 2001;24(2):275-290. (Pubitemid 32479421)
6. de Fost M, Hollak CE, Groener JE, et al. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood. 2006;108(3):830-835. (Pubitemid 44154614)
7. Cox TM, Aerts JM, Andria G, et al. Advisory Council to the European Working Group on Gaucher Disease. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis. 2003;26(6):513-526. (Pubitemid 37321530)
8. Aerts JM, Hollak CE, Boot RG, Groener JE, Maas M. Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis. 2006;29(2-3):449-456. (Pubitemid 43880650)
9. Aerts JM, van Breemen MJ, Bussink AP, et al. Biomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease. Acta Paediatr Suppl. 2008;97(457):7-14. (Pubitemid 351421284)
10. Hollak CE, Van Weely S, Van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest. 1994;93(3):1288-1292.
11. Boot RG, Verhoek M, De Fost M, et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood. 2004; 103(1):33-39. (Pubitemid 38029915)
12. Erikson A, Forsberg H, Nilsson M, Astrom M, Mansson JE. Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease. Acta Paediatr. 2006;95(3):312-317.
13. Meikle PJ, Whitfield PD, Rozaklis T, et al. Plasma lipids are altered in Gaucher disease: biochemical markers to evaluate therapeutic intervention. Blood Cells Mol Dis. 2008;40(3):420-427. (Pubitemid 351508448)
14. Groener JE, Poorthuis BJ, Kuiper S, Hollak CE, Aerts JM. Plasma glucosylceramide and ceramide in type 1 Gaucher disease patients: correlations with disease severity and response to therapeutic intervention. Biochim Biophys Acta. 2008;1781(1-2):72-78.
15. Ghauharali-van der Vlugt K, Langeveld M, Poppema A et al. Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease. Clin Chim Acta. 2008;389(1-2):109-113.
16. Raghavan SS, Mumford RA, Kanfer JN. Deficiency of glucosylsphingosine: beta-glucosidase in Gaucher disease. Biochem Biophys Res Commun. 1973;54(1):256-263.
17. Nilsson O, Svennerholm L. Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease, J Neurochem. 1982; 39(3):709-718. (Pubitemid 12034962)
18. Orvisky E, Park JK, LaMarca ME, et al. Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol Genet Metab. 2002; 76(4):262-270.
19. Schueler UH, Kolter T, Kaneski CR, et al. Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3. Neurobiol Dis. 2003;14(3):595-601. (Pubitemid 37543536)
20. Mistry PK, Liu J, Yang M, et al. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci U S A. 2010;107(45):19473-19478.
21. Lloyd-Evans E, Pelled D, Riebeling C, Futerman AH. Lyso- glycosphingolipids mobilize calcium from brain microsomes via multiple mechanisms. Biochem J. 2003;375(3):561-565. (Pubitemid 37433504)
22. Sun Y, Liou B, Ran H, et al. Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum Mol Genet. 2010;19(6): 1088-1097.
23. Ballabio A, Gieselmann V. Lysosomal disorders: from storage to cellular damage. Biochim Biophys Acta. 2009;1793(4):684-696.
24. Svennerholm L, Vanier MT, Månsson JE. Krabbe disease: a galactosylsphingosine (psychosine) lipidosis. J Lipid Res. 1980;21(1):53-64. (Pubitemid 10120438)
25. Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A. 2008;105(8): 2812-2817. (Pubitemid 351723626)
26. van Eijk M, van Roomen CP, Renkema GH, et al. Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. Int Immunol. 2005;17(11):1505-1512. (Pubitemid 41631326)
27. Witte MD, Kallemeijn WW, Aten J, et al. Ultrasensitive in situ visualization of active glucocerebrosidase molecules. Nat Chem Biol. 2010;6(12):907-913.
28. Schoonhoven A, Rudensky B, Elstein D, et al. Monitoring of Gaucher patients with a novel chitotriosidase assay. Clin Chim Acta. 2007;381(2): 136-139. (Pubitemid 46719145)
29. van Breemen MJ, de Fost M, Voerman JS, et al. Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1 beta levels in type 1 Gaucher disease. Biochim. Biophys. Acta. 2007; 1772(7):788-796. (Pubitemid 46891215)
30. Boven LA, Van Meurs M, Boot RG, et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol. 2004;122(3):359-369. (Pubitemid 39145540)
31. Bussink AP, Verhoek M, Vreede J, et al. Common G102S polymorphism in chitotriosidase differentially affects activity towards 4-methylumbelliferyl substrates. FEBS J. 2009;276(19):5678-5688.
32. Boot RG, Renkema GH, Verhoek M, et al. The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem. 1998;273(40): 25680-25685.
33. Pavlova EV, Deegan PB, Tindall J, et al. Potential biomarkers of osteonecrosis in Gaucher disease. Blood Cells Mol Dis. 2011;46(1):27-33.
34. van Breemen MJ, de Fost M, Maas M, et al. Different dose-dependent correction of MIP-1beta and chitotriosidase during initial enzyme replacement therapy. J Inherit Metab Dis. 2009;32(2): 274-279.
35. Cox-Brinkman J, van Breemen MJ, van Maldegem BT, et al. Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III. J Inherit Metab Dis. 2008;31(6):745-752.
36. Maas M, Hollak CE, Akkerman EM, Aerts JM, Stoker J, Den Heeten GJ. Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. AJR Am J Roentgenol. 2002;179(4):961-965.
37. Eitan Y, Abrahamov A, Phillips M, Elstein D, Zimran A. Sixteen years of prenatal consultations for the N370S/N370S Gaucher disease genotype: what have we learned? Prenat Diagn. 2010; 30(10):924-927.
38. Ohashi T, Hong CM, Weiler S, et al. Characterization of human glucocerebrosidase from different mutant alleles. J Biol Chem. 1991;266(6):3661-3667. (Pubitemid 21909263)
39. Bendikov-Bar I, Ron I, Filocamo M, Horowitz M. Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant. Blood Cells Mol Dis. 2011;46(1):4-10.
40. Aerts JM, Hollak CE. Plasma and metabolic abnormalities in Gaucher's disease. Baillieres Clin Haematol. 1997;10(4):691-709. (Pubitemid 28022203)
41. Deegan PB, Moran MT, McFarlane I, et al. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis. 2005;35(2):259-267. (Pubitemid 41267058)
42. Curtino JA, Caputto R. Enzymatic synthesis of glucosylsphingosine by rat brain microsomes. Lipids. 1972;7(8):525-527.
43. Vaccaro AM, Muscillo M, Suzuki K. Characterization of human glucosylsphingosine glucosyl hydrolase and comparison with glucosylceramidase. Eur J Biochem. 1985;146(2):315-321. (Pubitemid 15168858)
44. Dekker N, Voorn-Brouwer T, Verhoek M, et al. The cytosolic beta-glucosidase GBA3 does not influence type 1 Gaucher disease manifestation. Blood Cells Mol Dis. 2011;46(1):19-26.
45. Yamaguchi Y, Sasagasako N, Goto I, Kobayashi T. The synthetic pathway for glucosylsphingosine in cultured fibroblasts. J Biochem. 1994;116(3):704-710. (Pubitemid 24294806)
46. Tylki-Szymanska A, Czartoryska B, Vanier MT, et al. Non-neuronopathic Gaucher disease due to saposin C deficiency. Clin Genet. 2007;72(6): 538-542. (Pubitemid 350131059)
47. Vaccaro AM, Muscillo M, Tatti M, Salvioli R, Gallozzi E, Suzuki K. Effect of a heat-stable factor in human placenta on glucosylceramidase, glucosylsphingosine glucosyl hydrolase, and acid beta-glucosidase activities. Clin Biochem. 1987;20(6): 429-433. (Pubitemid 18035414)
48. Taketomi T, Kawamura N, Hara A, Murakami S. Comparative studies on chemical, hemolytic and diffusion-in-gel precipitation properties of various lysosphingolipids. Biochim Biophys Acta. 1976; 424(1):106-13.
49. Hannun YA, Bell RM. Functions of sphingolipids and sphingolipid breakdown products in cellular regulation. Science. 1989;243(4890):500-507. (Pubitemid 19048748)
50. van Breemen MJ, Rombach SM, Dekker N, et al. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim Biophys Acta. 2011;1812(1):70-76.